Research Square · Nov 16, 2026
Prognostic value of TyG-ABSI for all-cause and cardiovascular mortality across metabolic syndrome-related obesity phenotypes: a nationwide cohort study
By Xiang¹ Q, Xiang¹ M, Lu² M
Background Metabolic syndrome (MetS) and its related phenotypes are major drivers of cardiovascular mortality. The triglyceride-glucose (TyG) index and A Body Shape Index (ABSI) reflect insulin resistance and visceral adiposity, respectively. Their composite metric, TyG-ABSI, integrates these dimensions, but its predictive value for mortality across MetS-related metabolic health–obesity phenotypes remains unclear. Methods This study included 20,430 adults aged ≥ 20 years from the National Health and Nutrition Examination Survey (NHANES) 1999–2018. Participants were classified into four MetS-related phenotypes—metabolically healthy non-obesity (MHNO), metabolically healthy obesity (MHO), metabolically unhealthy non-obesity (MUNO), and metabolically unhealthy obesity (MUO)—according to body mass index and the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria. Weighted Cox regression, restricted cubic splines, Fine–Gray competing risk models, and time-dependent receiver operating characteristic (ROC) analysis were employed. Stratified analyses by estimated pulse wave velocity (ePWV) were performed to assess effect modification by an ePWV-related vascular aging process, supplemented by an exploratory association decomposition analysis. A preliminary cross-population comparison was also conducted in the CHARLS cohort (n = 7,239). Results During a median follow-up of 115 months, 2,524 all-cause and 774 cardiovascular deaths occurred. Each 1-SD increase in TyG-ABSI was associated with higher all-cause (HR 1.19, 95% CI 1.12–1.25) and cardiovascular mortality (HR 1.27, 95% CI 1.14–1.41). Associations were linear in MUNO and MUO, nonlinear in MHNO, and not statistically significant in MHO, though limited events warrant caution. TyG-ABSI achieved the highest 15-year AUCs in the overall population but showed no incremental value in MHO. Exploratory association decomposition analyses did not support causal inference, and sensitivity analyses were generally consistent. In a preliminary CHARLS comparison, the primary findings were not replicated, suggesting potential population-specific effects. Conclusions Across MetS-related obesity phenotypes, TyG-ABSI showed phenotype-dependent prognostic performance, with the most consistent independent value in MUNO. In MUO, its association was largely explained by conventional MetS components, whereas in MHO no significant association was detected. These findings suggest TyG-ABSI may aid risk stratification in MUNO, but its value in MUO is largely captured by conventional MetS components. Trial registration Clinical trial number: not applicable.